Uscom Limited · ASX:UCM
Uscom — Non-Deal Roadshow (November 2006)
31 slides from Uscom's roadshow presentation, Nov 28, 2006
Slide 1: Investor Road-Show
INVESTOR ROAD-SHOW Tuesday 28 November, 2006: Uscom Limited (ASX Code: UCM) today released details of an investor Road-Show in Sydney and Melbourne, as a follow-up to last Friday’s Annual General Meeting. The company announced in a letter to shareholders on October 25" that it had begun a program of
Slide 2: Uscom: The measure of life
Uscom The measure of life.
Slide 3: The USCOM Fundamentals
_ The USCOM Fundamentals: Listed: Dec 2003 (ASX Code: UCM) New shares issued: 8,000,000 Capital raised: A$16,000,000 Total Issued shares: 38,000,000 Top 20 shareholders: 81% of shares Rob Phillips: 16,590,000 shares 60% Gary Davey: 6,000,000 shares Uscom Limited was listed on the Australian Stock Ex
Slide 4: Uscom Achievements
Uscom Achievements: since vc in oct 02 * Built the USCOM TA. * Validated the device. « Achieved global regulatory approval. ¢ Finalist World Technology Awards - Time, Science, NYSE, CNN, Fortune. ¢ Established partnerships with some of the worlds leading Hospitals and Medical Practitioners. At Uscom
Slide 5: Uscom Achievements (continued)
agen BBS . Ges Achievement: since ve in oct 02 Uscom ; = ¢ Significantly grown IP portfolio and value. « Developed a product pathway for further generation products. « Developed sound management and IP development skills « Achieved sales in major markets with multiple sales in paediatrics. ¢ Continu
Slide 6: Non-invasive Management of Circulation
NON-INVASIVE MANAGEMENT Of CIRCULATION Let me review what the company has achieved in delivering its message to the medical community. Put simply, USCOM is a unique non-invasive solution for blood circulation management which we believe will change medical practice.
Slide 7: What is Uscom?
What is Uscom? A diagnostic & therapy management tool for circulation..... And itis non-invasive USCOM is a diagnostic tool and therapy guide for managing circulation. And critically it is non-invasive.
Slide 8: It is not a cardiology tool
lt is not a cardiology tool.... it is a comprehensive tool for managing circulation. Any person, any output, any where, any time! USCOM is NOT a cardiology tool. It is a comprehensive tool for managing circulation. SE etieesi elie
Slide 9: Improved Haemodynamics Management, Improved Outcomes
improved Haemodynamics Management improved Outcomes And this is important because improved hemodynamics results in improved patient outcomes.
Slide 10: Uscom is prepared for strategic development
« Useom is prepared for strategic development. « Contact with major companies for strategic alliances in U.S. & Europe * Incorporated UscomNC for North America. * Recruiting independent directors with deal-making skills «In discussion with professional advisers to assess strategic options. And event
Slide 11: FY06 target of 100+ unit sales
« FY ‘06 target of 100+ unit sales « Distribution weakness in some overseas markets « Addressing these issues * Distribution work essential for KOL network « Now have 150 customer sites worldwide « Sales continuing — but still in early stages of cycle We were disappointed in not achieving our stated
Slide 12: Technology Adoption Life Cycle
Technology Adoption Life Cycle innovators Geoffrey A. Moore, “Crossing the Chasm” At USCOM, we are not generally inclined to rely on marketing texts, but this chart from, “Crossing the Chasm” is an excellent summary of the process of adoption. And USCOM is at this stage, stil] at the “Innovator — Ea
Slide 13: Adoption
ADOPTION Hi USCOM is a brand new concept. It represents such a fundamental change in medical practice that the early years were bound to be difficult. Right from the outset, we have generated very high levels of INTEREST among clinicians and hospital administrators. But interest has to be converted
Slide 14: IP - Adding value
IP - Adding value Uscom has significant value in patent protected and in-house IP “Uscom has 24 separate patent cases directed to particular technologies with three new cases being added this year” Peter Treloar, Patent Attorney, Uscom 2005-6 Patent Report Building a product pipeline... wiiwiLscorn.
Slide 15: Major technology advancements
06 cope 3 major technology advancements Expansion of product pipeline: 5 new products | Growth in IP portfolio: Now 24 patent applications Further validation against gold standard USA market launch after FDA clearance Regulatory approval for Japan, Korea & Taiwan Direct Sales team for Australia: 16
Slide 16: Total Revenue, Costs and Cash Position
Total Revenue Total Costs Profit / (Loss) Cash receipts from customers Net operating cash outflow Cash in hand at 30 June 06 The Financial position of the company is sound. $1,716,529 ~ $5,158,809 ($3,345,267) — $1,119,622 $3,187,788 $7,222,322 For the first time, we exceeded one million dollars in
Slide 17: Units for FY06
Units for FY 06 USA 21 Asia 21 Australia 19 Europe 5 Other 1 TOTAL: 67 Year-On-Year: + 123% During FY 06, Uscom achieved a 123% year-on-year improvement in sales volume with 67 units sold for the year, with the US, Asia and Australia each representing approximately one-third of volume. This year, we
Slide 18: Growth
Growth Revenues from sales improved by 133% to A$1.1 million.
Slide 19: Net cash outflow, first quarter FY07
Net cash outflow * ran $1 089,651 Cash receipts from customers - : $258,596. ; “This includes $200,000 In manufacturing costs for inventory. The quarter showed a year-on-year improvement of $300,000... Vests vie otra) For the first quarter of FY 07, the company had net cash outflow of A$1 million. T
Slide 20: Market strategy
WMMASR OR Gorm att | USCOM has remained committed to a clear long term market strategy; a top- down approach, in 3 stages.
Slide 21: Market Strategy - Top Down
Market Strategy - TOP DOWN: WAC ADT Att | The company is currently still at the very apex of the pyramid, marketing its product to demanding centres of clinical excellence, the major teaching hospitals. Our marketing approach being focused on Emergency, Paediatrics and to lesser extent Intensive Car
Slide 22: Objectives for the year
q Release next product: OxyGOM q Advance argument for medical reimbursement q Achieve international recognition as standard of care q Build optimum sales structures in US and Europe q Restructure Board & Management q Conclude international strategic alliances q TARGET: Cash-flow positive Among the c
Slide 23: USCOM Applications
USCOM Applications: One of the challenges for USCOM is to keep the company focused on core priorities. It is challenging because USCOM has many applications across a variety of clinical uses.
Slide 24: USCOM Applications
“es USCOM Applications: ¢ Electrophysiology -¢ Drug trials *. Haemodialysis a ea eee TT ° Burns. ; « Paediatrics \+ Int. Care Heart Failure and Hypertension bo i - j = Psychiatry. ae ag Emergency ; Anaesthesia ~s Pregnancy. are «Liver transplantation __* Animal research (ethical) * Veterinary « Spor
Slide 25: Emergency and Paediatrics
EMERGENCY: Now in clinical use at key sites in Aust, Asia, Europe & U.S. Collaborative study at 7 hospitals. Dr Emanuel Rivers. Henry ford Hospital, Detroit. -. PAEDIATRICS: Now in clinical practice at 11 leading paediatrics sites. Great Osmond Steet Hospital, London So our 2 priority sectors are Em
Slide 26: Great Ormond Street Hospital quote
“At Great Ormond Street Hospital, © USCOM is the only method used for. cardiac output in the past 2 years!" _Drdoe Brierley Paediatric Intensive Care Great Ormond Street Hospital, London VanMiiscameaiiet! To put our role at Great Ormond Street into perspective, here is an authorised quote from Dr Jo
Slide 27: Paediatrics Luminary Sites
Paediatrics Luminary Sites x 11 * Children’s Hospital at Westmead : Sydney Children’s Hospital x 2 * Royal Children’s Hospital, Melbourne * Mercy Hospital, Melbourne : Duchess of Kent Children’s Hospital, Hong Kong : Shenzhen Children’s Hospital, Southern China + Saitama Paediatrics Hospital, Tokyo,
Slide 28: Primary Target Markets - Paediatrics
PRIMARY TARGET MARKETS - Paediatrics We are passionate about paediatrics. We believe USCOM will be embraced as a standard of care in this sector. Currently, clinicians treat their patients without measuring hemodynamics as current methods are too dangerous or inaccurate. USCOM is changing this!
Slide 29: Validation
Validation ¢ Over 50 studies presented ¢ 7 published in peer-reviewed journals - 27 new studies July 06 - Nov 06 Vests vie otra) The scientific validation of USCOM has already achieved critical mass. More than SO studies have been presented and peer-reviewed papers published in 7 important medical j
Slide 30: Summary
Summary....... * USCOM is ready for strategic change. ¢ Building a global business — regulatory approvals and Intellectual Property in place.: ¢ Achieving credibility against established methods, sales traction in target markets — « Dynamic growth with sound management. * Approaching breakeven with
Slide 31: Uscom as an investment opportunity
* USCOM is biodevice ~ Area of Australian achievement - in Bioscience (Resmed and Cochlear} . « Low Risk investment ¢ Device Built : « Extensive and compelling endorsements + Global regulatory : « Massive market ¢ Approaching breakeven with cash ¢ Multiple products ~ M&A friendly * Poised for rapid